{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T06:25:29Z","timestamp":1777443929930,"version":"3.51.4"},"reference-count":27,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2015,6,2]],"date-time":"2015-06-02T00:00:00Z","timestamp":1433203200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Clin Biochem"],"published-print":{"date-parts":[[2016,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Assessing prognosis is important in patients with neuroendocrine tumours of the small bowel as disease progression and survival is variable. We previously identified raised Neurokinin A as an independent indicator of poor prognosis and have shown that prognosis worsens when circulating Neurokinin A rises \u226550\u2009ng\/L. In the present study we have examined survival in relation to Neurokinin A concentrations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients in whom Neurokinin A rose \u226550\u2009ng\/L between January 1989 and December 2010 were identified. All circulating Neurokinin A concentrations were recorded and survival was followed up to 31 December 2014 or to death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Median survival, from the date when Neurokinin A was first \u226550\u2009ng\/L was 11.1 (2.0\u2013117.8) months if Neurokinin A remained \u226550\u2009ng\/L and 72.4 (4.8\u2013152.6) months when Neurokinin A was reduced below 50\u2009ng\/L and controlled below that concentration for \u22653 months (P\u2009&lt;\u20090.001). Survival was significantly better for patients attending the neuroendocrine tumour specialist clinic than for those not attending (P\u2009=\u20090.009). Comparing patients identified during 1989\u20132000, and those during 2001\u20132010, Neurokinin A was successfully reduced in the earlier period in 30.3% patients with median survival 23.2 (2.0\u2013152.6) months and this improved in 58.1% with median survival of 43.3 (2.0\u2013141.1) months in the later period (P\u2009=\u20090.019). Significance was greater between the earlier and later periods when only patients attending the neuroendocrine tumour clinic were compared (P\u2009=\u20090.016).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Circulating Neurokinin A\u2009\u2265\u200950\u2009ng\/L is a strong indicator of poor prognosis when Neurokinin A remains above this concentration. Lowering Neurokinin A below 50\u2009ng\/L indicates a significant improvement in prognosis (P\u2009&lt;\u20090.001). This prognostic indicator reflects improved treatment and survival in more recent years.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/0004563215592021","type":"journal-article","created":{"date-parts":[[2015,6,2]],"date-time":"2015-06-02T21:05:09Z","timestamp":1433279109000},"page":"259-264","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Raised circulating Neurokinin A predicts prognosis in metastatic small bowel neuroendocrine tumours. Lowering Neurokinin A indicates improved prognosis"],"prefix":"10.1177","volume":"53","author":[{"given":"Joy ES","family":"Ardill","sequence":"first","affiliation":[{"name":"Neuroendocrine Tumour Group, Royal Victoria Hospital, Belfast, Northern Ireland, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R","family":"McCance","sequence":"additional","affiliation":[{"name":"Neuroendocrine Tumour Group, Royal Victoria Hospital, Belfast, Northern Ireland, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy V","family":"Stronge","sequence":"additional","affiliation":[{"name":"Neuroendocrine Tumour Group, Royal Victoria Hospital, Belfast, Northern Ireland, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian T","family":"Johnston","sequence":"additional","affiliation":[{"name":"Neuroendocrine Tumour Group, Royal Victoria Hospital, Belfast, Northern Ireland, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2015,6,2]]},"reference":[{"key":"bibr1-0004563215592021","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.4377"},{"key":"bibr2-0004563215592021","first-page":"322","volume":"84","author":"Berge T","year":"1976","journal-title":"Acta Pathol Microbiol Scand"},{"key":"bibr3-0004563215592021","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-300831"},{"key":"bibr4-0004563215592021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000111698","volume":"87","author":"de Herder W","year":"2008","journal-title":"Neuroendocrinology"},{"key":"bibr5-0004563215592021","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0b013e3181ebb2a5"},{"key":"bibr6-0004563215592021","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.092320"},{"key":"bibr7-0004563215592021","doi-asserted-by":"publisher","DOI":"10.1677\/ERC-09-0042"},{"key":"bibr8-0004563215592021","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-002-6630-z"},{"key":"bibr9-0004563215592021","doi-asserted-by":"publisher","DOI":"10.1159\/000179900"},{"key":"bibr10-0004563215592021","first-page":"347","volume":"14","author":"Bodei L","year":"2010","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"bibr11-0004563215592021","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.2553"},{"key":"bibr12-0004563215592021","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0b013e31815e4557"},{"key":"bibr13-0004563215592021","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e3181d3d24a"},{"key":"bibr14-0004563215592021","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2009.0053"},{"key":"bibr15-0004563215592021","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.6587"},{"key":"bibr16-0004563215592021","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl144"},{"key":"bibr17-0004563215592021","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq670"},{"key":"bibr18-0004563215592021","unstructured":"Turner GB. MD thesis, QUB Queen\u2019s University, Belfast, 2004."},{"key":"bibr19-0004563215592021","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2010.09.001"},{"key":"bibr20-0004563215592021","doi-asserted-by":"publisher","DOI":"10.1258\/acb.2008.008039"},{"key":"bibr21-0004563215592021","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2012.08.057"},{"key":"bibr22-0004563215592021","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008215730767"},{"key":"bibr23-0004563215592021","doi-asserted-by":"crossref","unstructured":"Ardill Joy ES, Armstrong L, Smye M, et\u00a0al. Neuroendocrine tumours of the small bowel: interpretation of raised circulating chromogranin A, urinary 5 hydroxyindole acetic acid and neurokinin A.\n                      QJM\n                      . Epub ahead of print May 2015. DOI: 10.1093\/qjmed\/hcv095.","DOI":"10.1093\/qjmed\/hcv095"},{"key":"bibr24-0004563215592021","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/91.4.295"},{"key":"bibr25-0004563215592021","doi-asserted-by":"publisher","DOI":"10.1007\/BF00609184"},{"key":"bibr26-0004563215592021","first-page":"2124","volume":"26","author":"Rinke A","year":"2009","journal-title":"J Clin Oncol"},{"key":"bibr27-0004563215592021","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04693.x"}],"container-title":["Annals of Clinical Biochemistry: International Journal of Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0004563215592021","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0004563215592021","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0004563215592021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:22:20Z","timestamp":1777378940000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0004563215592021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,2]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["10.1177\/0004563215592021"],"URL":"https:\/\/doi.org\/10.1177\/0004563215592021","relation":{},"ISSN":["0004-5632","1758-1001"],"issn-type":[{"value":"0004-5632","type":"print"},{"value":"1758-1001","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,2]]}}}